An estimated 1 billion people between the ages of 30 and 69 across the globe suffer from sleep apnea, particularly ...

Please provide your email address to receive an email when new articles are posted on . Those with vs. without severe obstructive sleep apnea faced an 87% greater risk for being hospitalized with ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

Scientists have found that those living with obstructive sleep apnea (OSA) have a 71 per cent higher risk of cardiovascular ...

Please provide your email address to receive an email when new articles are posted on . Individuals with moderate to severe obstructive sleep apnea had increased odds of having neovascular AMD.

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has approved Zepbound, a GLP-1 weight-loss drug from Eli Lilly & Co., for the treatment of ...

Medically reviewed by Smita Patel, DO Key Takeaways Obstructive sleep apnea is a chronic sleep disorder characterized by breathing pauses and interruptions throughout the night. Living with ...

In much the same way that they’re designed to expand wearers’ upper airways, Vivos Therapeutics’ slate of oral appliances have now expanded their FDA indications, too. Collectively known as the ...

New research to be presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that those ...

New research has discovered a connection between microbleeds in the brain and obstructive sleep apnea. Design by MNT; Photography by Jackyenjoyphotography/Getty Images & Paul Biris/Getty Images A ...

Zepbound, Eli Lilly’s weight loss medication, became the first FDA-approved drug for obstructive sleep apnea Dec. 20. The new indication is for obese adults who experience moderate to severe ...